Sysmex Inostics
Laura Gauglitz is a highly skilled research associate currently working at Sysmex Inostics, focusing on clinical assay development and LDT validation since June 2022. Prior experience includes roles at the Leibniz-Institut für Virologie, where Laura served as a research assistant and master thesis student in systems arbovirology, completing a thesis on the characterization of Zika virus interacting proteins. Additional experience encompasses an internship at Umeå University on Tick-borne Encephalitis Virus assembly, a position in quality assurance at Allergopharma GmbH & Co. KG, and a bachelor's thesis related to a new BioID method in trypanosomes at Julius-Maximilians-Universität Würzburg. Academic credentials include a Master of Science in Molecular Life Sciences from the University of Hamburg and a Bachelor of Science in Biochemistry from Julius-Maximilians-Universität Würzburg.
This person is not in any offices
Sysmex Inostics
Leaders of the Global Liquid Biopsy Revolution As pioneers in blood-based cell-free tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last 10 years with the overall goal: to develop therapeutics that extend lives and provide diagnostics to monitor response to therapy, identify targetable resistance alterations, and detect minimal residual disease (MRD). SafeSEQ NGS technology can detect clinically relevant mutations in circulating tumor DNA (ctDNA) with robust detection as low as 0.03% mutant allele frequency (MAF), thus ensuring reliable molecular information for real-time therapy selection as well as monitoring of tumor response from across a broader range of genomic regions.